Elevated interleukin-25 and its association to Th2 cytokines in systemic lupus erythematosus with lupus nephritis

Autoři: Malarvili Selvaraja aff001;  Maha Abdullah aff001;  Masita Arip aff002;  Voon Kin Chin aff003;  Anim Shah aff004;  Syafinaz Amin Nordin aff005
Působiště autorů: Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia aff001;  Allergy and Immunology Research Centre, Institute for Medical Research, Jalan Pahang, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia aff002;  School of Biosciences, Taylor’s University, No. 1, Jalan Taylor’s, Subang Jaya, Selangor, Malaysia aff003;  Department of Medicine,Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia aff004;  Department of Medical Microbiology & Parasitology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia aff005
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0224707


Systemic lupus erythematosus (SLE) is an autoimmune disorder that is associated with lupus nephritis, initiated by the deposition of immune complexes in the kidney; subsequently, this induces the overexpression of cytokines. Lupus nephritis is known as one of the major clinical manifestations that affect the disease severity in SLE patients. An increased number of resident periglomerular and immune cells in the kidney has the potential to affect the equilibrium of different immune cell subsets, such as Th1, Th2, Th17, and Tregs, which may be central to the induction of tissue damage in kidney by exerting either proinflammatory or anti-inflammatory effects, or both. This equilibrium has yet to be confirmed, as new players such as IL-25 remain undiscovered. IL-25 is a cytokine of the IL-17 family, which stimulates Th2-mediated immune response when overly expressed. Thus, the aim of this research is to determine the plasma levels of IL-25 and Th2-associated cytokines (IL-4, IL-5, IL-6, IL-9, IL-10, IL-13) in SLE patients with (SLE-LN) and without lupus nephritis. Sixty-four (n = 64) SLE patients and fifteen (n = 15) healthy individuals were recruited. This study demonstrated that the IL-9, IL-10 and IL-25 had significantly increased expressions in SLE-LN, followed by SLE without LN, compared to healthy controls. Meanwhile, IL-5 and IL-6 had significantly reduced. No significant difference was observed with IL-13, while the level of IL-4 was undetectable. Furthermore, IL-9 and IL-10 were significantly correlated with the IL-25, and IL-25, IL-9 and IL-10 were positively correlated with the disease severity score, SLEDAI. In conclusion, IL-25 and its associated Th2 cytokines (IL-9 and IL-10) may be involved in SLE pathogenesis. These cytokines could be potential biomarkers in monitoring and predicting the disease severity during SLE pathogenesis.

Klíčová slova:

Creatinine – Cytokines – Pathogenesis – Platelets – Proteinuria – Basophils


1. Yap DYH and Chan TM. 2015. Lupus Nephritis in Asia: Clinical Features and Management. Kidney Diseases. 1(2):100–109. doi: 10.1159/000430458 27536670

2. Jakes RW, Bae SC, SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. 2012. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia- Pacific region: prevalence, incidence, clinical features and mortality. Arthritis Care research. 64(2): 159–168. doi: 10.1002/acr.20683 22052624

3. Hahn BH, McMahon M, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald J, Grossman JM. 2012. American College of Rheumatology guidelines for screening, case definition, treatment and management of lupus nephritis. Arthritis Care and Research. 64(6); 797–808. doi: 10.1002/acr.21664 22556106

4. Sigdel KR, Duan L, Wang Y, Hu W, Wang N, Sun Q, Liu Q, Liu X, Hou X, Cheng A, Shi G, Zhang Y. 2016. Serum Cytokines Th1, Th2 and Th17 Expression Profiling in Active Lupus Nephritis-IV: From a Southern Chinese Han Population. Mediators of Inflammation. 1–10.

5. Zhao M, Tang J, Gao F, Wu X, Liang Y, Yin H, and Lu Q. 2010. Hypomethylation of IL-10 and Il-13 Promoters in CD4+ T cells of patients with Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology. 2010:1–9.

6. Ferretti C, and La Cava A. 2016. Overview of the pathogenesis of systemic lupus erythematosus.Book Chapter. 55:62.

7. Hahn BH, McMahon M, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald J, Grossman JM. 2012. American College of Rheumatology guidelines for screening, case definition, treatment and management of lupus nephritis. Arthritis Care and Research. 64(6); 797–808. doi: 10.1002/acr.21664 22556106

8. Uhm WS, Na K, Song GW, et al. 2003. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology. 42(8): 935–938. doi: 10.1093/rheumatology/keg255 12730502

9. Charles N, Hardwick D, Daugas E, Illei GG, Rivera J. 2010. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nature Medicine. 16 (6); 701–707. doi: 10.1038/nm.2159 20512127

10. Fallon PG, Ballantyne SJ, Mangan NE, Barlow JL, Dasvarma A, Hewett DR, Mcllgorm A, Jolin HE, and McKenzie NJ. 2006. Identification of an interleukin (IL)-25-dependent cell population that provided IL-4, IL-5, and IL-13 at the onset of helminth expulsion. The Journal of Experimental Medicine. 203: 1105–1116. doi: 10.1084/jem.20051615 16606668

11. Gossner A, Peers A, Venturina V, Hopkins J. 2011. Expressed gene sequence of two variants of sheep interleukin 25. Vet Immunopathology. 139: 319–323.

12. Fort MMJ, Cheung D, Yen J, Li SM, Zurawski S, Lo S, Menon T, Clifford B, Hunte R, Lesley et al. 2001. IL-25 induces IL-4, IL-5 and IL-13 and Th2 associated pathologies in vivo. Immunity. 15: 985–995. doi: 10.1016/s1074-7613(01)00243-6 11754819

13. Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P. 1993. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. Journal of Immunology. 150:5445–5456.

14. Dalia AN, and Galal MAA. 2018. Interleukin 25 and Systemic Lupus Erythematosus. Journal of Clinical Immunology and Research. 1(1): 1–12.

15. Wong CK, Ho CYY, Li EK, Lam CWK. 2000. Elevation of proinflammatory cytokine (IL-18, IL-17, Il-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus. 9(8): 589–593. doi: 10.1191/096120300678828703 11035433

16. Chau CL, Amy HK, Susan M, and Joseph MA. 2013. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Therapeutic Advances in Musculoskeletal Disease. 5(4): 210–233. doi: 10.1177/1759720X13485503 23904865

17. McCarthy EM, Smith S, Lee RZ, Cunnane G, Doran MF, Donnelly S, Howard D, Connell PO, Kearns G, Gabhann JN, and Jefferies CA. 2014. The association of cytokines with disease activity and damage scores in systemic lupus erythematosus patients. Rheumatology. 53:1586–1594. doi: 10.1093/rheumatology/ket428 24706988

18. Brugos B, Vincze Z, Sipka S, Szegedi G, and Zeher M. 2012. Serum and urinary cytokine levels of SLE patients. Pharmazie. 67: 411–413. 22764573

19. Linden MWVD, Lopik TV, Aarden LA, Westendorp RGJ, and Huizinga TWJ. 2001. Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives. Annual Rheumatology Dis. 60: 237–241.

20. Petri M, Buyon J, Kim M. 1999. Classifications and definition of major flares in SLE clinical trials. Lupus. 8(8): 685–691. doi: 10.1191/096120399680411281 10568907

21. Ouyang H, Shi Y, Liu Z, Feng S, Li L, Su N, Lu Ying and Kong S. 2013. Increased Interleukin -9 and CD4+IL-9+ T cells in patients with systemic lupus erythematosus. Molecular Medicine Reports. 7: 1031–1037. doi: 10.3892/mmr.2013.1258 23291628

22. Yap DY, and Lai KN. 2010. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol:365083. doi: 10.1155/2010/365083 20467470

23. D’Cruz DP, Khamashta MA, Hughes GR. 2007. Systemic lupus erythematosus. Lanet. 369(9561):587–596.

24. Kasama T, Maeoka A, Oguro N. 2016. Clinical features of neuropsychiatric syndromes in systemic lupus erythematosus and other connective tissue diseases. clinical medicine insights. Clin Med Insights Arthritis Musculoskelet Disord 9: 1–8. doi: 10.4137/CMAMD.S37477 26819561

25. Shaharir SS, Hussein H, Rajalingham S, Said MSM, Gafor AHA, Mohd R, and Mustafar R. 2016. Damage in the multiethnic malaysian systemic lupus erythematosus (SLE) cohort: comparison with other cohorts worldwide. PloS one, 11(11), p.e0166270. doi: 10.1371/journal.pone.0166270 27846298

26. Sharma M, Bayry J. 2015. Autoimmunity: Basophils in autoimmune and inflammatory diseases. Journal of Nature Review Rheumatology.11(3):129–131.

27. Bayry J. 2016. Lupus Pathogenesis: role of IgE autoantibodies. Cell Research. 26(3):271–272. doi: 10.1038/cr.2016.12 26794873

28. Charles N, and Rivera J. 2011 Basophils and autoreactive IgE in the pathogenesis of systemic lupus erythematosus. Current Allergy Asthma Rep. 11(5): 378–387

29. Narayanan K, Marwaha V, Shanmuganandan K, Shankar S. 2010. Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-DsDNA antibodies. Medical Journal of Armed Forces India. 66(2): 102–107.

30. Bosch X, Lozano F, Cervera R, Casals MR and Min B. 2011. Basophils, IgE and Autoantibody-Mediated Kidney Disease. The Journal of Immunology. 186: 6083–6090. doi: 10.4049/jimmunol.1002648 21597041

31. Atta AM, Sousa CM, Carvalho EM, and Sousa-Atta ML. 2004. Immunoglobulin E and systemic lupus erythematosus. Braz. J. Med. Biol. Res. 37:1497–1501. doi: 10.1590/s0100-879x2004001000008 15448870

32. Angkasekwinai P, Srimanote P, Wang YH, Pootong A, Sakolvaree Y, Pattanapanyasat K, Chaicumpa W, Chaiyaroj S, Dong C. 2013. IL-25 promotes efficient protective immunity against T. spiralis infection by enhancing antigen-specific IL-9 response. Infection and immunity, pp.IAI-00646.

33. Wu L, Zepp JA, Qian W, Martin BN, Ouyang W, Yin W, Bunting KD, Aronica M, Erzurum S, and Li X. 2015. A Novel IL-25 –Signaling Pathway through STAT5. The Journal of Immunology.194: 1–8.

34. Carneiro JRM, Fuzii HT, Kayser C, Alberto FL, Soares FA, Sato EI, Andrade LEC. 2011. IL-2, IL-5, TNF-α and IFN-γ mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesions. Clinical Science. 66(1); 77–82.

35. Mohan C, Adams S, Stannik V, Datta SK. 1993. A major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 177:1367–1381. doi: 10.1084/jem.177.5.1367 8478612

36. Horwitz DA, Gray JD, Behrendson SC. et al. 1998. Decreased production of IL-12 and other Th1-type cytokines in patients with recent–onset systemic lupus erythematosus. Arthritis Rheum. 41: 838–844. doi: 10.1002/1529-0131(199805)41:5<838::AID-ART10>3.0.CO;2-S 9588735

37. Peterson E, Robertson AD, and Emlen W. 1996. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus. 5(6): 571–575. doi: 10.1177/096120339600500603 9116699

38. Doria A, Ghirardello A, Laccarinoc L, Zampieri S, Punzi L, Tarricone E, Ruffatti A, Sulli A, Sarzi-Puttini PC, Gambari PF, Cutolo M. 2004. Pregnancy, cytokines and disease activity in systemic lupus erythematosus. Arthritis Rheumatology. 51(6): 989–995.

39. Godsell J, Rudloff I, Kandane-Rathnayake R, Hoi A, Nold MF, Morand E, et al. 2016. Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. Scientific Reports. 6. doi: 10.1038/srep34604 27708376

40. Yin Z, Huang J, He W, Cao Z, Luo X, Zhang C, and Ye Z. 2014. Serum level of eight cytokines in Han Chinese patients with systemic lupus erythematosus using multiplex fluorescent microsphere method. Central European Journal of Immunology. 39(2); 228–235. doi: 10.5114/ceji.2014.43728 26155129

41. Ran C, and Jian-Huua X. 2012. The abnormality and clinical significance of T-helper 9 cells and interleukin-9 in patients with rheumatoid arthritis. Chinese Journal of Rheumatology. 32(2).

42. Khan IH, Krishnan VV, Ziman M, et al. 2009. A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. Cytometry B Clin Cyto. 76:159–168.

43. Gadani SP, Cronk JC, Norris GT, Kipnis J. 2012. Interleukin-4: A cytokine to Remember. Journal of Immunology. 189(9): 4213–4219.

44. Takatsu K. Interleukin-5 and IL-5 receptor in health and diseases. Proceeding of the Japan Academy, Series B Physical and Biological Sciences. 87(8): 463–485.

45. Sewell WA, Scurr LL, Orphanides H, Kinder S, Ludowyke RI. 1998. Induction of Interleukin-4 and Interleukin-5 expression in mast cells is inhibited by glucorcorticoids. Clinical and Diagnostic Laboratory Immunology. 5(1): 18–23. 9455873

Článek vyšel v časopise


2019 Číslo 11